Gland Pharma announced a robust performance for Q2 FY26, with revenue up by 6% year-over-year and profit after tax (PAT) increasing by 12%. The company’s core business maintained profitable growth with strong margin expansion. Positive contributions came from the USA and Europe, with growth rates of 10% and 16%, respectively, and Cenexi experienced a 21% top-line increase. The company anticipates continued growth in upcoming quarters.
Financial Performance Highlights
Gland Pharma reported a strong first half of FY26, demonstrating consistent growth and profitability. Here are the key highlights from the consolidated financial results:
- Revenue from operations increased by 6% year-over-year to ₹14,869 Mn.
- Profit After Tax (PAT) grew by 12% year-over-year to ₹1,837 Mn.
- EBITDA increased by 6% year-over-year to ₹3,139 Mn.
- USA grew by 10% and Europe by 16%. Cenexi’s top-line increased by 21%.
Margin Expansion
Gland Pharma showcased strong margin expansion during the quarter:
- Gross Profit Margin stood at 63%.
- EBITDA Margin was reported at 21%.
- PAT Margin increased to 12%.
Segment Performance
The company’s performance varied across different geographical segments:
- USA: Revenue increased by 10% year-over-year.
- Europe: Revenue increased by 16% year-over-year.
Key Business Updates
Several strategic initiatives and developments contributed to the company’s performance:
- R&D investments increased to ₹614 Mn.
- Launched seven new molecules in the USA.
- Filed six ANDAs and received five approvals.
Cenexi Financials
Cenexi reported a revenue increase of 21%. The Fontenay facility’s GMP certificate was renewed through the end of CY2026.
Source: BSE
